Invesaro

Stocks Comparison

InnovAge vs GeneDx: revenue, profit, margins and growth compared

InnovAge brought in $989.7M of revenue in fiscal 2026, GeneDx $427.5M in fiscal 2025. Revenue changed by +15.9% at InnovAge and +40.0% at GeneDx on the year before, so GeneDx grew faster. InnovAge kept -0.3% of its revenue as net profit, GeneDx -4.9%. Free cash flow was $50.4M at InnovAge and $14.3M at GeneDx.

Side by side, latest fiscal year

INNVWGS
Fiscal year endedFY2026 (June 30, 2026)FY2025 (December 31, 2025)
Revenue$989.7M$427.5M
Revenue growth+15.9%+40.0%
Net income-$2.5M-$21M
Net margin-0.3%-4.9%
Free cash flow$50.4M$14.3M
Free cash flow margin5.1%3.3%
Earnings per share (diluted)-$0.02-$0.73
Cash$97.9M$105M
Debt$48.8M$54.5M
Price to earningsn/an/a
Market value$1.2B$2.6B
Dividend yieldn/an/a
Rank by revenue in sector#145 of 523 · Health care#199 of 523 · Health care

Over the years

Revenue
INNV FY2021: $567.2MINNV FY2021: $637.8MINNV FY2022: $698.6MINNV FY2023: $688.1MINNV FY2024: $763.9MINNV FY2025: $853.7MINNV FY2026: $989.7MWGS FY2019: $196.2MWGS FY2020: $179.3MWGS FY2021: $212.2MWGS FY2022: $234.7MWGS FY2023: $202.6MWGS FY2024: $305.5MWGS FY2025: $427.5MFY19FY20FY21FY22FY23FY24FY25FY26
INNV $989.7MWGS $427.5M
Net income
INNV FY2021: $26.3MINNV FY2021: -$44MINNV FY2022: -$6.5MINNV FY2023: -$40.7MINNV FY2024: -$21.3MINNV FY2025: -$30.3MINNV FY2026: -$2.5MWGS FY2019: -$29.7MWGS FY2020: -$241.3MWGS FY2021: -$245.4MWGS FY2022: -$549MWGS FY2023: -$175.8MWGS FY2024: -$52.3MWGS FY2025: -$21MFY19FY20FY21FY22FY23FY24FY25FY26
INNV -$2.5MWGS -$21M
Net margin
INNV FY2021: 4.6%INNV FY2021: -6.9%INNV FY2022: -0.9%INNV FY2023: -5.9%INNV FY2024: -2.8%INNV FY2025: -3.6%INNV FY2026: -0.3%WGS FY2019: -15.1%WGS FY2020: -134.6%WGS FY2021: -115.6%WGS FY2022: -233.9%WGS FY2023: -86.8%WGS FY2024: -17.1%WGS FY2025: -4.9%FY19FY20FY21FY22FY23FY24FY25FY26
INNV -0.3%WGS -4.9%
Revenue growth
INNV FY2021: +12.4%INNV FY2022: +9.5%INNV FY2023: -1.5%INNV FY2024: +11.0%INNV FY2025: +11.8%INNV FY2026: +15.9%WGS FY2020: -8.6%WGS FY2021: +18.3%WGS FY2022: +10.6%WGS FY2023: -13.7%WGS FY2024: +50.8%WGS FY2025: +40.0%FY20FY21FY22FY23FY24FY25FY26
INNV +15.9%WGS +40.0%
Free cash flow
INNV FY2021: $32MINNV FY2021: -$25.1MINNV FY2022: -$10.9MINNV FY2023: -$3.1MINNV FY2024: -$44.8MINNV FY2025: $26.6MINNV FY2026: $50.4MWGS FY2019: -$30.7MWGS FY2020: -$117.2MWGS FY2021: -$199.8MWGS FY2022: -$326.3MWGS FY2023: -$185.4MWGS FY2024: -$34MWGS FY2025: $14.3MFY19FY20FY21FY22FY23FY24FY25FY26
INNV $50.4MWGS $14.3M

Fiscal years as each company reports them; the two may end in different months.

Questions about InnovAge and GeneDx

Which is bigger by revenue, InnovAge or GeneDx?

InnovAge is bigger by revenue: $989.7M in fiscal 2026, against $427.5M for GeneDx in fiscal 2025.

Which keeps more of its revenue as profit, InnovAge or GeneDx?

InnovAge had a net margin of -0.3% in fiscal 2026; GeneDx had -4.9% in fiscal 2025.

Which grew revenue faster, InnovAge or GeneDx?

In their latest fiscal years revenue changed by +15.9% at InnovAge and +40.0% at GeneDx.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies